US 7,321,033 B2 | ||
3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof | ||
Devron R. Averett, Cardiff By The Sea, Calif. (US); Stephen E. Webber, San Diego, Calif. (US); Joseph R. Lennox, San Diego, Calif. (US); Erik J. Rueden, Santee, Calif. (US); David Louis Clark, San Diego, Calif. (US); and Alan Xin Xiang, Chula Vista, Calif. (US) | ||
Assigned to Anadys Pharmaceuticals, Inc., San Diego, Calif. (US) | ||
Filed on Jun. 07, 2004, as Appl. No. 10/861,430. | ||
Application 10/861430 is a continuation in part of application No. 10/305061, filed on Nov. 27, 2002, granted, now 6,924,271. | ||
Claims priority of provisional application 60/333460, filed on Nov. 27, 2001. | ||
Prior Publication US 2005/0070556 A1, Mar. 31, 2005 | ||
Int. Cl. C07H 19/00 (2006.01); C07H 19/044 (2006.01); C07D 239/00 (2006.01); C07D 239/70 (2006.01); C07D 471/00 (2006.01); C07D 487/00 (2006.01); C07D 491/00 (2006.01); C07D 239/02 (2006.01); A01N 43/90 (2006.01); A61K 31/519 (2006.01) |
U.S. Cl. 536—27.2 [536/27.1; 536/27.13; 536/28.6; 544/245; 544/253; 544/255; 544/294; 544/322; 544/330; 544/332; 514/259.2] | 11 Claims |
1. A compound represented by Formula I
![]() R1a, R1b, and R1c are independently H, —C(O)R3, a racemic, L-, or D- amino acid group —C(O)CH2NHR4, —C(O)CH(C1-6 alkyl)NHR4, or R1b and R1c are collectively —C(O)—, which together with the oxygen atoms forms a five-membered carbonate ring;
R2 is H;
R3 is a C1-18 alkyl; and
R4 is H, —C(O)CH(C1-6 alkyl)NH2, or —C(O)CH(CH2-aryl)NH2;
wherein the alkyl and aryl moieties of the foregoing groups are optionally substituted with substituents independently selected
from halo, cyano, nitro, trifluoromethyl, trifluoromethoxy, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, hydroxy, C1C6 alkoxy, —NH-alkyl, —NH-alkyl —N(alkyl)2, —NH-aryl, —N(alkyl)(aryl), —N(aryl)2, —NHCHO, —NHC(O)aryl, —NHC(O)aryl, —N(alkyl)C(O)H, —N(alkyl)C(O)alkyl, —N(aryl)C(O)H, —N(aryl)C(O)alkyl, —NHCO2alkyl, —N(alkyl)CO2alkyl, —NHC(O)NH2, —N(alkyl)C(O)NH2, —NHC(O)NH-alkyl, —NHC(O) N(alky)2, —N(alkyl)C(O)NH-alkyl, N(alkyl)C(O) N(alkyl)2, —NHSO2-alkyl, —N(alkyl)SO2-alkyl, —C(O)alkyl, —C(O)aryl, —OC(O)alkyl, —OC(O)aryl, —CO2-alkyl, —CO2-aryl, —CO2H, —C(O)NH2, —C(O)NH-alkyl, —C(O)N(alkyl)2, —C(O)NH-aryl, —C(O)N(aryl)2, —C(O)N(alkyl)(aryl), —S(O)alkyl, —S(O)aryl, —SO2alkyl, —SO2aryl, —SO2NH2, —SO2NH-alkyl, and —SO2N(alkyl)2;
or a pharmaceutically acceptable salt thereof.
|